Phibro Animal Health shares surge 12.0% after-hours following Q2 2026 earnings beat, 26% sales growth, and raised guidance.

Phibro Animal Health Corp (PAHC) surged 12% in after-hours trading following the release of its Q2 2026 earnings results, which highlighted 26% growth in animal health sales, 41% higher adjusted EBITDA, and a 21% year-over-year revenue increase. The company exceeded EPS expectations by 27.9% and raised full-year guidance for sales and EBITDA, reflecting strong performance in the MFA portfolio and favorable market conditions in poultry and protein sectors. The stock’s post-earnings rally aligns with the CFO’s attribution of margin expansion to pricing strategies, product mix, and operational efficiency, as well as management’s confidence in sustained growth under the Phibro Forward initiative.